Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience

Detalles Bibliográficos
Autores principales: Barbieri, Emiliano, Maccaferri, Monica, Leonardi, Giovanna, Giacobbi, Francesca, Corradini, Giorgia, Lagreca, Ivana, Barozzi, Patrizia, Potenza, Leonardo, Marasca, Roberto, Luppi, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646578/
https://www.ncbi.nlm.nih.gov/pubmed/36104630
http://dx.doi.org/10.1007/s00277-022-04978-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646578/
https://www.ncbi.nlm.nih.gov/pubmed/36104630
http://dx.doi.org/10.1007/s00277-022-04978-6

Ejemplares similares